rdrp-in-2

RdRP-IN-2 is an RNA-dependent RNA polymerase (RdRp) inhibitor that significantly inhibits SARS-CoV-2 RdRp with an IC50 of 41.2 µM and also inhibits Feline coronavirus (FIPV) replication.

PC786 is a potent and selective non-nucleoside RSV L-protein polymerase inhibitor for inhalation therapy of RSV infections, with antiviral activity against RSV-A (IC50=0.09-0.71 nM) and RSV-B (IC 50=1.3-50.6 nM), and the ability to inhibit RSV RNA-dependent RNA polymerase in HEp-2 cells ( RdRp).

SARS-CoV-IN-6 (Compound 17) acts as an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, demonstrating an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. This compound reduces the cytopathic effects of single-round infectious particles (SRIP) infected with SARS-CoV-1 and SARS-CoV-2 replicons and inhibits the expression of SARS-CoVN proteins. The EC50 values for SRIP based on SARS-CoV-1 and SARS-CoV-2 replicons are 0.12 µM and 1.47 µM, respectively.

MTI013 is a selective inhibitor of SARS-CoV-2 nsp14 Mtase (IC50: 2.98 µM) and an antiviral agent (IC50: 10.33 µM in HCoV-229E infected Huh7 cells). Additionally, MTI013 demonstrates synergistic antiviral effects when used in conjunction with the RdRp inhibitor SHEN26.

HNC-1664 is an orally active inhibitor of RNA-dependent RNA polymerase (RdRP). It exhibits broad-spectrum antiviral activity against coronaviruses, including SARS-CoV-2 wild type and its variants (XBB.1.18, HK.3.1, BF.7.14, BA.1, HCoV-229E, HCoV-OC43), as well as arenaviruses. HNC-1664 also demonstrates anti-infective efficacy in a mouse model infected with the SARS-CoV-2 Delta variant.

13-TP is an inhibitor of SARS-CoV-2. It effectively suppresses in vitro RNA synthesis catalyzed by the central replication-transcription complex (C-RTC, nsp12-nsp7-nsp82) of SARS-CoV-2. 13-TP fully inhibits RdRp polymerase activity and obstructs the complete extension of some primer RNAs.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.

RdRP-IN-7, a RNA-dependent RNA polymerase (RdRp) inhibitor, demonstrates efficacy against SARS-CoV-2 infection with an inhibitory concentration (IC50) of 8.2 μM and (IC90) of 14.1 μM, alongside a cytotoxic concentration (CC90) of 79.1 μM, rendering it suitable for antiviral research [1].

SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivative, exhibits anti-SARS-CoV-2 properties with an effective concentration (EC50) of 64.8 μM in VeroE6 TMPRSS2 cells and inhibits SARS-CoV-2 RdRp activity [1].

BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor, is effective orally and can inhibit various SARS-CoV-2 variants. It exhibits EC 50 values of 0.62 µM for SARS-CoV-2 and 0.14 µM for HCoV-229E, demonstrating potent anti-pancoronavirus activity at submicromolar concentrations. Additionally, BPR3P0128 displays synergistic antiviral effects when used in combination with Remdesivir [1].

NITD-2 is a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly. Dengue virus (DENV) is the most prevalent mosquito- borne viral pathogen in humans. Neither vaccine nor antiviral therapy is currently available for DENV.

Lamivudine triphosphate (3TCTP), a phosphorylated form of the nucleoside analogue Lamivudine, inhibits the reverse transcriptase of HIV or HBV, blocking viral replication through chain termination. It also acts as an inhibitor of the RdRp activity of the HCVNS5B subunit. Additionally, Lamivudine triphosphate can be incorporated into nascent RNA by SARS-CoV-2 RdRp, thereby preventing mutations in the newly synthesized SARS-CoV-2 RNA.

HeE1-2Tyr, a pyridobenzothiazole compound, is a potent inhibitor of flavivirus RNA-dependent RNA polymerases (RdRp). It significantly inhibits the RdRp activity of West Nile, Dengue, and SARS-CoV-2 in vitro, with an IC50 of 27.6 µM.